The Lawyer Global Litigation Top 50 report is the only ranking of international law firms by litigation and arbitration revenue and is essential reading for anyone seeking to benchmark their litigation and dispute resolution practices...
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Novartis has announced the results of its first panel review since the company’s $40bn takeover of Alcon, with three magic circle firms – Allen & Overy, Freshfields Bruckhaus Deringer and Linklaters – securing spots on the global roster along with two US firms.
Pharma company Novartis’s new panel, called the legal preferred firm programme, is comprised of 25 firms divided into four groups – global firms, US country firms, US country specialist firms and US country specialist intellectual property firms.
The shake-up is intended to help Novartis develop long-term strategic partnerships with law firms and is one of the first changes under group general counsel Felix Ehrat, who joined the company from Swiss firm Bär & Karrer in October 2011 (31 October 2011) after the incumbent – Thomas Werlen – left for Quinn Emanuel Urquhart & Sullivan.
US firms Morrison & Foerster and Simpson Thacher & Bartlett join the magic circle firms on the global firm panel. The global firm line-up is almost unchanged since the company’s previous panel review in 2009 (28 September 2009) except that Simpson Thacher, which was an Alcon panel firm, has replaced White & Case.
White & Case did, however, make the company’s US country firm panel, along with Arnold & Porter, Cravath Swaine & Moore and Kaye Scholar.
“We believe the programme’s renewed focus on relationships creates a win-win environment,” said Ehrat. “The commitments we’re making will lead to increased efficiency and effectiveness.”
Under the preferred firm programme, panel members will be required to come together once a year at an annual summit to “further relationships and develop a deeper understanding of Novartis business”.